Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset ...
Novo Nordisk will be happy with the results after Pfizer has dropped two SCD assets in recent years. Credit: JHVEPhoto / ...
Zacks Investment Research on MSN
NVO's etavopivat hits key goals in phase III sickle cell disease study
Novo Nordisk NVO announced meeting both co-primary endpoints in a late-stage study of its investigational candidate, etavopivat, for adults and adolescents with sickle cell disease (SCD). The data ...
Zacks Investment Research on MSN
Agios stock sinks 23% as NVO's PKR activator meets goal in SCD study
Shares of Agios Pharmaceuticals AGIO declined sharply by 23% on Monday after Novo Nordisk NVO announced positive top-line ...
Topline data for the once-daily PKR activator etavopivat demonstrate a 27% reduction in vaso-occlusive crises and a robust hematologic response in patients with SCD.
The epidemiology of sudden cardiac deaths (SCDs) was turned on its head Thursday, with research showing that in reality, ...
A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood. People with sickle cell disease (SCD) say a ...
"We need effective anti-bias interventions to improve care for patients with sickle cell disease, and this deeper understanding is a step in the right direction," said the study author.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results